Angiotensin-converting enzyme 2 (ACE2)

Where the papers sit

10 papers from the last 6 months study Angiotensin-converting enzyme 2 (ACE2) directly · updated from PubMed 10 Oct 2026

• ACE2-Targeted Antiviral Strategies

  ACE2 is being used both as a viral-entry target and as a delivery handle against SARS-CoV-2. Proposed approaches include IL-27 gene therapy, virtual-screened entry inhibitors, and ACE2-PNA conjugates that exploit endocytosis for intracellular antiviral activity. Virus-like particles provide a related platform for displaying or delivering protein-lipid constructs. Evidence remains largely preclinical, leaving durability across variants and in vivo efficacy unresolved.

  4 papers · 40%

• Antibody Escape in SARS-CoV-2

  Antibody design is shifting toward forecasting escape rather than testing existing antibodies only after variants emerge. Deep mutational scanning and machine learning map receptor-binding-domain substitutions that weaken polyclonal serum recognition. Iterative prediction and experiments aim to keep antibody combinations effective against new variants. The open challenge is translating escape maps into durable combination therapies with reliable protection against unforeseen mutations.

  3 papers · 30%

• Others — ACE2-Linked Disease Biology

  ACE2-linked disease biology spans obesity-related cardiovascular and reproductive dysfunction, preeclampsia-associated protein changes, and IgA nephropathy. High-fat-diet models connect ACE2 downregulation with weight gain, glucose intolerance, and adverse cardiac or pregnancy outcomes. Clinical biomarker and computational studies extend the association to preeclampsia and renal immune pathways. The findings do not establish one shared mechanism or therapeutic direction across these conditions.

  3 papers · 30%